# Case study 3: Near-floor query — retrieval ceiling limits all patterns

**Query ID:** `a45c277e-55d9-4e7f-b1de-37fc2e19daf6`
**Source:** litqa2
**Domain:** scientific_literature
**Difficulty:** complex

## Query text

> Which of the following genes has been shown to be a specific marker for parvalbumin interneurons in the molecular and fusiform layers of the dorsal cochlear nucleus?

**Expected topics:** Ogfrl1

## 3-judge mean overall score per pattern (base patterns only)

| Pattern | Mean overall score |
|:---|---:|
| base_p0 | 0.446 |
| base_p1 | 0.599 |
| base_p2 | 0.489 |
| base_p3 | 0.480 |
| base_p4 | 0.456 |
| base_p5 | 0.610 |
| base_p6 | 0.428 |
| base_p7 | 0.196 |
| base_p8 | 0.531 |
| base_p9 | 0.308 |
| base_p10 | 0.206 |

## Key-dimension verdicts

**base_p5**

| Judge | Dimension | Satisfied | Reasoning (truncated) |
|:---|:---|:---:|:---|
| claude_sonnet | analytical_depth | Y | The report integrates findings from multiple brain regions and methodologies to arrive at a synthesized conclusion about the DCN knowledge g |
| claude_sonnet | analytical_depth | Y | The report identifies transcriptomic similarity as a fundamental challenge to marker discovery, going beyond surface description. |
| claude_sonnet | analytical_depth | Y | Connections are drawn between PV-IN molecular characteristics, their functional role in the DCN, and clinical implications for auditory diso |
| claude_sonnet | analytical_depth | Y | The report clearly distinguishes well-established PV-IN findings in other brain regions from the uncertain/unexplored territory of the DCN. |
| gpt52 | analytical_depth | Y | The report attempts cross-source synthesis by contrasting regional findings rather than presenting isolated summaries. |
| gpt52 | analytical_depth | Y | It goes beyond description by discussing functional mechanisms and methodological limitations affecting marker discovery. |
| gpt52 | analytical_depth | Y | The report draws connections between molecular markers, circuit roles, and clinical implications. |
| gpt52 | analytical_depth | Y | It distinguishes between established general PV markers and unverified/absent DCN-specific evidence. |
| claude_sonnet | citation_quality | Y | Specific claims are consistently attributed to numbered inline citations. |
| claude_sonnet | citation_quality | Y | Consistent numbered bracket format [n] is used throughout with a reference list. |
| claude_sonnet | citation_quality | Y | 43 distinct sources are cited, appropriate for a specialized neuroscience topic. |
| claude_sonnet | citation_quality | Y | Different sections draw from different subsets of sources. |
| gpt52 | citation_quality | N | Claims are not attributed to clearly named sources in a way that allows verification. |
| gpt52 | citation_quality | Y | The citation style is consistent even though many entries are low-quality placeholders. |
| gpt52 | citation_quality | Y | The report cites more than the minimum number of distinct sources, even if many are not well-specified. |
| gpt52 | citation_quality | Y | Sections do not rely on a single citation and instead reference multiple sources across the report. |
| claude_sonnet | factual_accuracy | Y | Core characterization of PV-INs as fast-spiking GABAergic neurons with PVALB expression is consistent with established neuroscience knowledg |
| claude_sonnet | factual_accuracy | Y | Neuroscience terminology (scRNA-seq, snRNA-seq, GABAergic, PVALB) is used correctly and precisely. |
| claude_sonnet | factual_accuracy | Y | The 2,700+ transcript count is attributed to cited sources and is consistent with published RiboTag profiling results. |
| claude_sonnet | factual_accuracy | Y | The 2025 ScienceDirect paper represents the latest research, correctly placed in the current research context. |
| claude_sonnet | factual_accuracy | Y | Comparative claims about DCN vs other brain regions regarding PV-IN gene marker knowledge are supported by the cited RiboTag studies. |
| claude_sonnet | factual_accuracy | Y | The conclusion about DCN-specific knowledge gaps is consistently stated across all sections. |
| claude_sonnet | factual_accuracy | Y | Technical limitations of scRNA-seq and the challenge of identifying unique markers due to transcriptomic similarity are accurately represent |
| claude_sonnet | factual_accuracy | Y | Current transcriptomic techniques (scRNA-seq, snRNA-seq, RiboTag) and a 2025 paper on molecular programs are cited as current state-of-the-a |
| gpt52 | factual_accuracy | N | Several claims are plausible, but the central claim that no specific DCN PV markers exist is not supported with verifiable sources, so accur |
| gpt52 | factual_accuracy | Y | Technical terminology is generally used correctly and in context. |
| gpt52 | factual_accuracy | N | A specific number is given without a traceable, named citation, so its accuracy cannot be verified from the report. |
| gpt52 | factual_accuracy | N | There is no historical timeline presented to evaluate for correctness. |
| gpt52 | factual_accuracy | N | Comparative claims are asserted but not supported by specific, named, citable evidence tied to the DCN context. |
| gpt52 | factual_accuracy | Y | No direct internal contradictions are apparent across sections. |
| gpt52 | factual_accuracy | Y | Method limitations and caveats are explicitly acknowledged and reasonably described. |
| gpt52 | factual_accuracy | N | The report gestures at general SOTA methods but does not correctly identify the current SOTA evidence base for DCN PV markers. |
| claude_sonnet | information_recall | Y | Key facts about PV-IN markers (PVALB, SOM, NPY, VIP, CCK) and the DCN-specific knowledge gap are retrieved and presented. |
| claude_sonnet | information_recall | Y | Quantitative data on transcript counts from profiling studies is provided to contextualize the comparative scope. |
| claude_sonnet | information_recall | N | The majority of citations are 'Web Search Synthesis' entries without URLs. Few actual primary research articles are cited (only arxiv prepri |
| claude_sonnet | information_recall | Y | Markers, co-expression patterns, profiling techniques, and DCN-specific anatomy are all covered. |
| gpt52 | information_recall | N | The report does not identify which gene (from the implied answer choices) is a specific marker, instead concluding none are known. |
| gpt52 | information_recall | N | No quantitative data directly relevant to the DCN molecular/fusiform PV-interneuron marker question is provided. |
| gpt52 | information_recall | N | The report does not clearly identify or cite authoritative/seminal primary sources specific to PV markers in DCN layers. |
| gpt52 | information_recall | N | Given the query asks for a specific marker, omitting any concrete candidate gene evidence (or explicit negative evidence from DCN studies) i |

**base_p1**

| Judge | Dimension | Satisfied | Reasoning (truncated) |
|:---|:---|:---:|:---|
| claude_sonnet | analytical_depth | Y | Good synthesis across diverse sources. |
| claude_sonnet | analytical_depth | Y | Analysis identifies important patterns and mechanisms. |
| claude_sonnet | analytical_depth | Y | Cross-cutting connections are drawn. |
| claude_sonnet | analytical_depth | Y | Clear distinction between established and contested claims. |
| gpt52 | analytical_depth | Y | The report combines information across sources to reach an overall judgment rather than only listing source-by-source summaries. |
| gpt52 | analytical_depth | N | The analysis does not meaningfully explore mechanisms, trade-offs, or layer/cell-type specificity patterns beyond a surface-level conclusion |
| gpt52 | analytical_depth | Y | The report draws connections between anatomical context (DCN layers), marker biology (PV), and methodological approaches (scRNA-seq). |
| gpt52 | analytical_depth | Y | It clearly distinguishes established PV marker usage in cortex/hippocampus from contested/unsupported specificity in DCN layers. |
| claude_sonnet | citation_quality | Y | Consistent inline attribution. |
| claude_sonnet | citation_quality | Y | Citation format is uniform. |
| claude_sonnet | citation_quality | Y | Source count is adequate given the specialized topic. |
| claude_sonnet | citation_quality | Y | Different source sets across sections. |
| gpt52 | citation_quality | Y | Many claims are attributed using bracketed inline citations tied to the reference list. |
| gpt52 | citation_quality | Y | Citation formatting is consistent throughout the report. |
| gpt52 | citation_quality | Y | The report cites more than the minimum of 5 distinct sources. |
| gpt52 | citation_quality | Y | Different sections draw on different sources rather than relying on a single reference. |
| claude_sonnet | factual_accuracy | Y | Core neuroscience facts are accurate. |
| claude_sonnet | factual_accuracy | Y | Neuroscience terminology is precise. |
| claude_sonnet | factual_accuracy | Y | Specific numbers and structural facts are accurate. |
| claude_sonnet | factual_accuracy | Y | No chronological errors. |
| claude_sonnet | factual_accuracy | Y | Comparative claims are supported. |
| claude_sonnet | factual_accuracy | Y | No contradictions. |
| claude_sonnet | factual_accuracy | Y | Limitations are accurately characterized. |
| claude_sonnet | factual_accuracy | N | The absence of Ogfrl1 discussion suggests a critical current-state-of-art omission if this gene has been identified in the literature as a D |
| gpt52 | factual_accuracy | N | This broad claim is not substantiated and is likely inaccurate given the existence of brainstem/cochlear nucleus transcriptomic work, making |
| gpt52 | factual_accuracy | Y | Key technical terms (PV+, interneurons, scRNA-seq, DCN layers) are used in a generally correct and precise way. |
| gpt52 | factual_accuracy | N | The report provides a specific number without a clearly authoritative primary source, so its accuracy cannot be verified from the report. |
| gpt52 | factual_accuracy | N | The report does not present a historical timeline/chronology to evaluate for correctness. |
| gpt52 | factual_accuracy | N | The report implies comparative suitability of markers but does not provide supported comparative performance claims tied to evidence for PV  |
| gpt52 | factual_accuracy | Y | The report’s main claims are consistent across sections without clear internal contradictions. |
| gpt52 | factual_accuracy | Y | Limitations and caveats (lack of direct DCN-layer evidence, reliance on other regions, need for scRNA-seq) are explicitly and appropriately  |
| gpt52 | factual_accuracy | N | The report does not correctly or concretely identify the state-of-the-art for DCN PV interneuron marker discovery, instead making broad unsu |
| claude_sonnet | information_recall | Y | Key facts for answering the marker identification question are present. |
| claude_sonnet | information_recall | Y | Some quantitative context is provided, appropriate for the available evidence. |
| claude_sonnet | information_recall | N | The most seminal neuroanatomy papers on DCN organization and parvalbumin interneurons are not cited. |
| claude_sonnet | information_recall | Y | Given the specialized and limited literature, coverage of available evidence is appropriate. |
| gpt52 | information_recall | N | The query asks which gene is a specific marker, but the report does not identify any gene that has been shown to be specific for PV interneu |
| gpt52 | information_recall | N | The only quantitative figure provided is about cortex and is not relevant to PV interneurons specifically in the DCN molecular/fusiform laye |
| gpt52 | information_recall | N | The report does not demonstrate use of the most authoritative/seminal primary literature focused on DCN PV interneuron markers beyond one re |
| gpt52 | information_recall | N | Given the report’s inability to name a specific marker gene, it likely omits widely-available primary evidence or candidate marker discussio |

**base_p8**

| Judge | Dimension | Satisfied | Reasoning (truncated) |
|:---|:---|:---:|:---|
| claude_sonnet | analytical_depth | Y | The report integrates therapeutic potential and ethical implications into a unified analysis rather than separately summarizing each. |
| claude_sonnet | analytical_depth | Y | The report identifies mechanistic connections between PV interneuron dysfunction and neurodegenerative disease pathology. |
| claude_sonnet | analytical_depth | Y | The report connects the general advances in gene therapy to the specific gap in DCN-targeted research, identifying the translation challenge |
| claude_sonnet | analytical_depth | N | The report does not clearly differentiate between well-validated therapeutic targets (OTOF gene therapy) and more speculative DCN-specific a |
| gpt52 | analytical_depth | Y | There is some cross-source synthesis rather than purely source-by-source summaries. |
| gpt52 | analytical_depth | Y | The report includes analysis of mechanisms and trade-offs beyond surface description. |
| gpt52 | analytical_depth | Y | It draws connections between scientific, therapeutic, and ethical aspects. |
| gpt52 | analytical_depth | N | It does not consistently distinguish well-established findings from speculative or contested claims. |
| claude_sonnet | citation_quality | N | Many key claims trace to anonymous web search syntheses, particularly for the DCN-specific claims which are the core of the query. |
| claude_sonnet | citation_quality | Y | Citation format is consistent throughout using numbered brackets. |
| claude_sonnet | citation_quality | Y | 44 references far exceed the minimum threshold with several high-quality peer-reviewed sources. |
| claude_sonnet | citation_quality | N | The ethical sections over-rely on two anonymous web search synthesis entries, and PV interneuron review articles are repeatedly cited across |
| gpt52 | citation_quality | N | Attribution is often not to clearly named, specific sources in a way that supports the claims. |
| gpt52 | citation_quality | N | Citation formatting is inconsistent and sometimes incomplete. |
| gpt52 | citation_quality | Y | The report cites an adequate number of distinct sources for the broad scope it chose. |
| gpt52 | citation_quality | Y | It does not rely on a single source and draws from multiple references across sections. |
| claude_sonnet | factual_accuracy | Y | The characterization of PV interneurons as fast-spiking inhibitory neurons with calcium-binding parvalbumin expression is factually accurate |
| claude_sonnet | factual_accuracy | Y | Technical terms including mechanotransduction, adeno-associated virus (AAV), base editing, CRISPR-Cas9, and parvalbumin are used correctly. |
| claude_sonnet | factual_accuracy | Y | The 1-8% prevalence figure for OTOF mutations in congenital hearing loss is consistent with published epidemiological data. |
| claude_sonnet | factual_accuracy | Y | No incorrect historical claims are made about the chronology of gene therapy or PV interneuron research development. |
| claude_sonnet | factual_accuracy | N | Age-dependent efficacy comparisons are made without specific quantitative data on the magnitude of the difference between neonatal and adult |
| claude_sonnet | factual_accuracy | Y | No internal contradictions are present; therapeutic targets and ethical concerns are consistently described. |
| claude_sonnet | factual_accuracy | Y | The report accurately identifies key limitations of gene therapy approaches including delivery barriers, age-dependence, and off-target effe |
| claude_sonnet | factual_accuracy | N | The report correctly identifies current gene therapy tools but overstates the clinical translation for hearing loss (describing 'early-stage |
| gpt52 | factual_accuracy | N | Key claims are misaligned with the question (hair-cell/hearing-loss genes are not shown here as DCN PV interneuron markers), undermining fac |
| gpt52 | factual_accuracy | Y | Technical terminology is generally used correctly even though it is applied to an off-target scope. |
| gpt52 | factual_accuracy | N | The report provides few checkable numeric claims and does not substantiate them with clearly traceable, specific supporting sources in-text. |
| gpt52 | factual_accuracy | N | There is no explicit timeline to evaluate, so chronology is not demonstrated as correct. |
| gpt52 | factual_accuracy | N | Comparative claims are made but not supported with concrete, attributable evidence in the text. |
| gpt52 | factual_accuracy | Y | No direct internal contradictions are apparent across sections. |
| gpt52 | factual_accuracy | Y | It includes reasonable caveats about gene-editing and targeting limitations. |
| gpt52 | factual_accuracy | N | State-of-the-art relevant to the actual query (DCN PV interneuron marker identification) is not correctly identified or summarized. |
| claude_sonnet | information_recall | Y | The report includes key facts about PV interneuron biology, marker gene candidates, therapeutic applications, and ethical considerations rel |
| claude_sonnet | information_recall | Y | The report provides quantitative data on mutation prevalence and gene therapy outcomes. |
| claude_sonnet | information_recall | Y | The report cites authoritative sources including Nature, NIDCD, JCI, and leading neuroscience journals for PV interneuron research. |
| claude_sonnet | information_recall | N | The core query asks for specific marker genes for PV interneurons in the DCN molecular and fusiform layers specifically; the report does not |
| gpt52 | information_recall | N | It never answers the core question of which gene is a specific marker for PV interneurons in the specified DCN layers. |
| gpt52 | information_recall | N | No quantitative data relevant to PV interneuron marker specificity in DCN layers is provided. |
| gpt52 | information_recall | N | The report does not identify or rely on authoritative/seminal sources specifically about DCN parvalbumin interneuron marker genes. |
| gpt52 | information_recall | N | Widely-available evidence directly addressing DCN PV interneuron markers is effectively omitted, leaving the question unanswered. |

## Report excerpts (first ~200 words)

### base_p5

```text
# Identification of Specific Gene Markers for Parvalbumin Interneurons in the Dorsal Cochlear Nucleus ## Abstract Parvalbumin interneurons (PV-INs) are fast-spiking GABAergic inhibitory neurons that play a critical role in maintaining excitation-inhibition balance, generating gamma oscillations, and modulating neural circuits. While parvalbumin (PVALB) is widely recognized as the primary molecular marker for PV-INs across various brain regions, the molecular and genetic characteristics of PV-INs in the molecular and fusiform layers of the dorsal cochlear nucleus (DCN) remain poorly understood. This research report synthesizes findings from multiple studies to evaluate whether specific gene markers, beyond PVALB, have been identified for PV-INs in the DCN. Despite significant advancements in transcriptomic profiling techniques, such as single-cell RNA sequencing (scRNA-seq) and RiboTag RNAseq, no unique gene markers for PV-INs in the DCN have been conclusively identified. This contrasts with findings from other brain regions, such as the hippocampus and dorsal striatum, where thousands of enriched transcripts have been discovered. Co-expressed markers like somatostatin (SOM), neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), and cholecystokinin (CCK) have been identified in PV-INs in other regions, but their relevance to the DCN remains unverified. This report highlights the need for region-specific studies employing advanced molecular profiling techniques to ...
```

### base_p1

```text
# Research Report: Identification of Specific Markers for Parvalbumin Interneurons in the Molecular and Fusiform Layers of the Dorsal Cochlear Nucleus ## Abstract This research report investigates whether parvalbumin (PVALB) or any other gene serves as a specific marker for parvalbumin-expressing interneurons in the molecular and fusiform layers of the dorsal cochlear nucleus (DCN). The DCN is a critical auditory processing center, and identifying specific markers for its interneurons is essential for understanding its functional organization. While parvalbumin (PVALB) is a well-established marker for fast-spiking interneurons in several brain regions, the evidence regarding its specificity in the molecular and fusiform layers of the DCN is inconclusive. This report synthesizes findings from 12 sources, including research papers and documentation, to evaluate the current state of knowledge. The findings suggest that while parvalbumin is a prominent marker for inhibitory interneurons in various brain regions, it lacks specificity for parvalbumin interneurons in the molecular and fusiform layers of the DCN. The report highlights the need for further studies, particularly those employing single-cell RNA sequencing (scRNA-seq), to identify specific markers for these interneurons and to elucidate their roles in auditory processing. --- ## Introduction The dorsal cochlear nucleus (DCN) is a key auditory brainstem ...
```

### base_p8

```text
# Identifying Specific Marker Genes for Parvalbumin Interneurons in the Dorsal Cochlear Nucleus: A Synthesis of Research Directions ## Abstract Parvalbumin (PV) interneurons are critical for maintaining excitatory-inhibitory balance and regulating network oscillations in the central nervous system. Their dysfunction is implicated in various neurological and auditory disorders, including epilepsy, schizophrenia, Alzheimer’s disease, and tinnitus. This report synthesizes findings from two promising research directions to address the query: identifying specific marker genes for PV interneurons in the molecular and fusiform layers of the dorsal cochlear nucleus (DCN). The first direction evaluates the potential of identified marker genes as therapeutic targets for auditory and neurodegenerative disorders, while the second examines the ethical implications of using gene-based markers to manipulate neuronal subtypes. Evidence from 21 high-quality sources highlights genes such as *OTOF*, *GJB2*, *TMC1*, and *Mecp2* as potential therapeutic targets for auditory and neurodegenerative conditions. Advanced gene-editing technologies, such as CRISPR-Cas9 and adenine base editing, have shown promise in preclinical models, with some early-stage human trials underway. However, challenges such as delivery barriers, age-dependent efficacy, and off-target effects remain significant hurdles. Ethical concerns include safety risks, privacy violations, informed consent, and societal implications, particularly regarding the manipulation of neuronal subtypes like PV ...
```

## Interpretation

The best-scoring pattern reaches 0.610 on this query, which does not meet the original max<=0.40 'universal failure' threshold (no query in the eval set falls below 0.50). This query represents the lowest retrieval ceiling observed across all 90 queries. The pattern is still meaningful: all architectures are substantially constrained by available sources, confirming that source retrieval quality is the primary performance bottleneck.

> **Methodology note:** Original threshold (max<=0.40) was not met by any query; this case study uses the lowest-ceiling query available (max=0.610).
